Arcus Biosciences Inc (RCUS)
Working capital turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 258,000 | 117,000 | 112,000 | 382,882 | 77,517 |
| Total current assets | US$ in thousands | 1,016,000 | 831,000 | 1,067,000 | 1,262,000 | 735,815 |
| Total current liabilities | US$ in thousands | 226,000 | 184,000 | 193,000 | 166,000 | 121,669 |
| Working capital turnover | 0.33 | 0.18 | 0.13 | 0.35 | 0.13 |
December 31, 2024 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $258,000K ÷ ($1,016,000K – $226,000K)
= 0.33
The working capital turnover ratio for Arcus Biosciences Inc has shown some fluctuations over the past five years.
As of December 31, 2020, the working capital turnover ratio was 0.13, indicating that the company generated revenue 0.13 times for every dollar invested in working capital. This suggests a relatively low efficiency in utilizing its working capital during that period.
By December 31, 2021, the working capital turnover ratio improved significantly to 0.35, showing a substantial increase in efficiency in turning working capital into revenue. This indicates that the company was able to generate more revenue for every dollar invested in working capital during this period.
However, by December 31, 2022, the ratio dropped back to 0.13, representing a decline in efficiency compared to the previous year.
Subsequently, as of December 31, 2023, the working capital turnover ratio slightly increased to 0.18, signifying a moderate improvement in efficiency.
Lastly, by December 31, 2024, the ratio rose again to 0.33, demonstrating a notable improvement in utilizing working capital to generate revenue.
Overall, while there were fluctuations in the working capital turnover ratio over the five-year period, the company showed moments of improved efficiency in utilizing its working capital to generate revenue.
Peer comparison
Dec 31, 2024